Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Day One Biopharmaceuticals CEO Jeremy Bender sold shares of the company's common stock between May 1 and May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Jeremy Bender, CEO of Day One Biopharmaceuticals, sold shares of the company's common stock between May 1 and May 3, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on October 3, 2023.
- On May 1, 2024, 70,051 shares were sold at a weighted average price of $17.8753, with individual prices ranging from $17.84 to $18.04.
- On May 2, 2024, 6 shares were sold at a weighted average price of $17.9375, with individual prices ranging from $17.85 to $17.955.
- On May 3, 2024, 9,154 shares were sold at a weighted average price of $17.852, with individual prices ranging from $17.84 to $17.96.
- Following these transactions, Jeremy Bender directly owns 642,602 shares of Day One Biopharmaceuticals.
- Additionally, he indirectly owns 221,837 shares through The Jeremy Bender 2022 Grantor Retained Annuity Trust, 300,025 shares through The Jeremy Bender 2023 Grantor Retained Annuity Trust, 251,636 shares through The Melissa Bender 2022 Grantor Retained Annuity Trust, and 270,226 shares through The Melissa Bender 2023 Grantor Retained Annuity Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, potentially leading to short-term stock price volatility.
Industry Context
Sales by company executives are a normal part of corporate activity, especially when executed under pre-arranged trading plans like Rule 10b5-1, which are designed to prevent accusations of insider trading.
Stakeholder Impact
- Shareholders may react to the news of executive stock sales, although the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-10-03 | Date the Rule 10b5-1 trading plan was adopted by Jeremy Bender |
| 2024-05-01 | First day of reported stock sales by Jeremy Bender |
| 2024-05-02 | Second day of reported stock sales by Jeremy Bender |
| 2024-05-03 | Third day of reported stock sales by Jeremy Bender |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.